Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis

被引:67
作者
Wong, V
Fu, AXL
George, J
Cheung, NW
机构
[1] Westmead Hosp, Dept Endocrinol & Diabet, Westmead, NSW 2145, Australia
[2] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Storr Liver Unit, Westmead, NSW 2145, Australia
关键词
D O I
10.1046/j.1365-2265.2002.01553.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND AND OBJECTIVE It has been well documented that treatment of chronic hepatitis B and C infection with interferon alpha (IFN-alpha) can lead to the induction of thyroid autoantibodies and hypothyroidism. Thyrotoxicosis, however, is less frequently observed and less well characterized. PATIENTS AND METHODS We reviewed the medical records of patients who developed thyrotoxicosis while receiving IFN-alpha for either chronic hepatitis B or C infection at Westmead Hospital between 1996 and March 2001. RESULTS Ten patients (four males and six females) were found to have biochemical thyrotoxicosis. The patients could be divided into two groups with different characteristics. The first group consisted of six patients who had clinical manifestations consistent with Graves' disease, with either diffuse uptake in thyroid scintigraphy and/or positive thyroid-stimulating antibodies. They all required prolonged treatment with antithyroid medications. The second group included three patients who had transient thyrotoxicosis, with progression to hypothyroidism after resolution of thyrotoxicosis. CONCLUSION Our study suggests that IFN therapy may provoke two different forms of thyrotoxicosis: a Graves' disease picture or a biphasic thyroiditis pattern. The two entities should be differentiated, as they have different implications for treatment.
引用
收藏
页码:793 / 798
页数:6
相关论文
共 37 条
[21]   HEPATITIS-C VIRUS-INFECTION, ALPHA-INTERFERON THERAPY AND THYROID-DYSFUNCTION [J].
MARCELLIN, P ;
POUTEAU, M ;
BENHAMOU, JP .
JOURNAL OF HEPATOLOGY, 1995, 22 (03) :364-369
[22]  
McHugh PR, 1999, COMMENTARY, V107, P6
[23]   Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C [J].
McHutchison, JG ;
Gordon, SC ;
Schiff, ER ;
Shiffman, ML ;
Lee, WM ;
Rustgi, VK ;
Goodman, ZD ;
Ling, MH ;
Cort, S ;
Albrecht, JK .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1485-1492
[24]  
MekkakiaBenhabib C, 1996, ANN ENDOCRINOL-PARIS, V57, P419
[25]   ANTITHYROID HORMONE ANTIBODIES INDUCED BY INTERFERON-ALPHA [J].
PAPO, T ;
OKSENHENDLER, E ;
ZEMBART, M ;
LEGER, A ;
CLAUVEL, JP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (06) :1484-1486
[26]  
PATERON D, 1991, HEPATOLOGY, V14, pA77
[27]   Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus [J].
Poynard, T ;
Marcellin, P ;
Lee, SS ;
Niederau, C ;
Minuk, GS ;
Ideo, G ;
Bain, V ;
Heathcote, J ;
Zeuzem, S ;
Trepo, C ;
Albrecht, J .
LANCET, 1998, 352 (9138) :1426-1432
[28]   AUTOIMMUNITY AND THYROID-FUNCTION IN PATIENTS WITH CHRONIC ACTIVE HEPATITIS TREATED WITH RECOMBINANT INTERFERON ALPHA-2A [J].
PREZIATI, D ;
LAROSA, L ;
COVINI, G ;
MARCELLI, R ;
RESCALLI, S ;
PERSANI, L ;
DELNINNO, E ;
MERONI, PL ;
COLOMBO, M ;
BECKPECCOZ, P .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1995, 132 (05) :587-593
[29]   ALPHA-INTERFERON FOR INDUCTION OF REMISSION IN HAIRY-CELL LEUKEMIA [J].
QUESADA, JR ;
REUBEN, J ;
MANNING, JT ;
HERSH, EM ;
GUTTERMAN, JU .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (01) :15-18
[30]   AUTOIMMUNITY AFTER ALPHA-INTERFERON THERAPY FOR MALIGNANT CARCINOID-TUMORS [J].
RONNBLOM, LE ;
ALM, GV ;
OBERG, KE .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (03) :178-183